PubMed · 13166606
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1954. THIS IS Harrogate.. https://pubmed.ncbi.nlm.nih.gov/13166606/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
The use of water for medical treatment is probably as old as mankind. Until the middle of the last century, spa treatment, including hydrotherapy and balneotherapy, remained popular but went into decline especially in the Anglo-Saxon world with the development of effective analgesics. However, no analgesic, regardless of its potency, is capable of eliminating pain, and reports of life-threatening adverse reactions to the use of these drugs led to renewed interest in spa therapy. Because of methodologic difficulties and lack of research funding, the effects of 'water treatments' in the relief of pain have rarely been subjected to rigorous assessment by randomised, controlled trials. It is our opinion that the three therapeutic modalities must be considered separately, and this was done in the present paper. In addition, we review the research on the mechanism of action and cost effectiveness of such treatments and examine what research might be useful in the future.
The aim of this paper was to study the variations of radon and daughter nuclei during treatment in the thermal spas of Lesvos Island (Greece). For this purpose, in the thermal spas of Lesvos we have measured the radon concentrations of thermal waters, as well as indoor radon, daughter and coarse particle (>500 nm) concentrations. Various instruments and procedures were employed for measurements. Radon concentrations of thermal waters were found to lie in the range 10 Bq l(-1) and 304 Bq l(-1). Concentration peaks both for radon, radon daughter and coarse particle, were found to appear during filling of baths in the treatment process. The doses delivered to the bathers during treatment were in the range of 0.00670-0.1279 mSv per year, while the doses delivered to personnel were below 20 mSv per year.